At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KALA KALA BIO
Market Closed 11-15 16:00:00 EST
6.70
-0.06
-0.89%
盘后6.70
+0.000.00%
16:09 EST
High6.87
Low6.66
Vol9.95K
Open6.66
D1 Closing6.76
Amplitude3.16%
Mkt Cap30.87M
Tradable Cap18.67M
Total Shares4.61M
T/O67.51K
T/O Rate0.36%
Tradable Shares2.79M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
KALA BIO Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.